We inform you that Angelini Holding S.p.A. uses cookies (small files saved on your hard disk) to improve your browsing experience on this site. Angelini Holding S.p.A. uses third party cookies that allow third parties to access personal data collected during navigation. By continuing to browse the site, by accessing any area of it or selecting an element of it (for example, an image or a link) you consent to the use of cookies. At the following link you will find our extended information on cookies with a description of the categories present and links to the information of third parties as independent data controllers and you will have the opportunity to decide which cookies to authorize or whether to deny consent to all or only some cookies CONTINUE

Pharmaceuticals

Angelini Pharma

Angelini Pharma is the pharmaceutical division of the Angelini Group.

Angelini Pharma is a private international group, leader in the Healthcare and Wellbeing, committed to identifying health solutions with a prevalent focus on the areas of Central Nervous System (CNS), including pain, and Rare Diseases. The Company is also a leading player in the Consumer Health sector, with highly successful self-medication drugs both in Italy and abroad.

Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 15 countries employing more than 2.700 people. Its products are marketed in about 70 countries even through strategic alliances with leading international pharmaceutical groups.

Angelini Pharma is an integrated pharmaceutical company with extensive and well-recognised Research and Development programmes, in addition to world-class production facilities and international marketing activities of key compounds and leading drugs in many sectors. Strategic partnerships with international companies complete and expand the geographical areas where Angelini Pharma operates.
Over the years, the Research and Development teams at Angelini Pharma have identified several important molecules such as trazodone and benzydamine, and are currently involved in innovative research projects in the areas of Nervous System Diseases and Disorders, Pain and Inflammation and Rare Diseases, with a particular commitment to the research of new treatments for the paediatric population.
The research at Angelini Pharma embraces public-private partnerships with recognised academic institutions and centres of global importance. The Scientific Network and Partnerships have both an important role in creating innovation.

 

Angelini Pharma in figures

  1. 2,750 Employees
  2. 5 Production plants worldwide
  3. 50% Turnover from abroad
  4. 70 Countries in which products are marketed

Angelini Pharma’s italian production facilities in Ancona (Finished Products), Aprilia (Raw Materials) and Casella (Amuchina-brand products) are at the forefront of technologies, industry standards and environmental protection, thanks to the use and integration of renewable sources.
In Barcelona, Spain, the company produces food supplements such as Pastillas Juanola.
In March 2020, Angelini Pharma acquired the production plant in Albany (Georgia), a global supplier for ThermaCare Heatwrap.

Angelini Pharma has offices in Italy, Spain, Portugal, Austria, Poland, Czech Republic, Slovakia, Hungary, Germany, Romania, Bulgaria, Greece, Turkey, Russia, and USA.

In line with its international strategies, Angelini Pharma has promoted pathways for development in countries with high growth potential, with both targeted acquisitions and enhancement of existing structures.
Moreover, important strategic alliances with leading pharmaceutical groups with a global footprint allow the distribution of Angelini Pharma products worldwide.

In the last 10 years, the percentage sales outside Italy has grown constantly, reaching about 50% of total pharma sales today.

Visit our website